Last edition
News about "treatment-resistant schizophrenia (TRS)"
Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study
Newron’s ENIGMA-TRS 2 study continues outside the US, with expanded sites and enrollment in Europe, Asia and Latin America; topline data expected in Q1 2027.
Treatment-Resistant Schizophrenia (TRS) | 28/09/2026 | By News Bureau
Newron Provides Update Following Type A Meeting with the US FDA
Newron has provided an update following its Type A meeting with the US Food and Drug Administration (FDA), outlining the steps required to resume US enrollment in the phase 3 ENIGMA-TRS 2 schizophrenia study.
Treatment-Resistant Schizophrenia (TRS) | 04/07/2026 | By News Bureau | 204
Newron Pharmaceuticals Pauses US Enrollment in ENIGMA-TRS 2 Study
Newron Pharmaceuticals pauses enrolment at US sites in ENIGMA-TRS 2 study, while global ENIGMA-TRS 1 trial continues with more than 400 patients enrolled.
Treatment-resistant Schizophrenia (TRS) | 02/05/2026 | By News Bureau | 180
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy